Novel Variants Near the Central Domain of RYR1 in Two Malignant Hyperthermia-Susceptible Families from Taiwan
暂无分享,去创建一个
[1] R. Robinson,et al. Mutations in RYR1 in malignant hyperthermia and central core disease , 2006, Human mutation.
[2] A. Covacci,et al. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia , 2006, Human mutation.
[3] M. Klein,et al. Characterization of Ryanodine Receptor–mediated Calcium Release in Human B Cells: Relevance to Diagnostic Testing for Malignant Hyperthermia , 2006, Anesthesiology.
[4] Y. Hayashi,et al. Malignant Hyperthermia in Japan: Mutation Screening of the Entire Ryanodine Receptor Type 1 Gene Coding Region by Direct Sequencing , 2006, Anesthesiology.
[5] H. Yeh,et al. Denaturing High Performance Liquid Chromatography Screening of Ryanodine Receptor Type 1 Gene in Patients with Malignant Hyperthermia in Taiwan and Identification of a Novel Mutation (Y522C) , 2005, Anesthesia and analgesia.
[6] R. Litman,et al. Malignant hyperthermia: update on susceptibility testing. , 2005, JAMA.
[7] T. Nelson,et al. Malignant Hyperthermia in North America: Genetic Screening of the Three Hot Spots in the Type I Ryanodine Receptor Gene , 2004, Anesthesiology.
[8] M. Siegemund,et al. Molecular Genetic Testing for Malignant Hyperthermia Susceptibility , 2004, Anesthesiology.
[9] D. Venzon,et al. Patients with Malignant Hyperthermia Demonstrate an Altered Calcium Control Mechanism in B Lymphocytes , 2002, Anesthesiology.
[10] J. Antognini,et al. Testing for Malignant Hyperthermia , 2002, Anesthesiology.
[11] A. Urwyler,et al. B-lymphocytes from Malignant Hyperthermia-susceptible Patients Have an Increased Sensitivity to Skeletal Muscle Ryanodine Receptor Activators* , 2001, The Journal of Biological Chemistry.
[12] A. Urwyler,et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. , 2001, British journal of anaesthesia.
[13] F. Lehmann-Horn,et al. Genetics and pathogenesis of malignant hyperthermia , 2000, Muscle & nerve.
[14] A. Kunselman,et al. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. , 1998, Anesthesiology.
[15] A. Kunselman,et al. The Sensitivity and Specificity of the Caffeine‐Halothane Contracture Test: A Report from the North American Malignant Hyperthermia Registry , 1998 .
[16] F. Lehmann-Horn,et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low‐risk subjects , 1997, Acta anaesthesiologica Scandinavica.
[17] A. Herrmann-Frank,et al. Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle. , 1996, The Biochemical journal.
[18] A. Localio,et al. A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.
[19] G. Comi,et al. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia , 1998, Human mutation.